Serum dipeptidyl peptidase IV activity in patients with non-alcoholic fatty liver disease

Aims: Previous reports found increased serum dipeptidyl peptidase IV (DPPIV) activity in patients (pts) with different chronic liver diseases and also recently a few DPPIV inhibitors were introduced into the treatment of type 2 diabetes mellitus (DM2). Aims: We aimed to study the serum DPPIV activity in pts with non-alcoholic fatty liver disease (NAFLD) due to the phenomenon that a significant proportion of NAFLD pts harbours characteristics overlapping with the metabolic disorder. Therefore we performed 75gCH oral glucose tolerance test in pts with previously unknown DM2 and NAFLD. Known DM2 NAFLD pts received…